Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
R. C. Coombes,
P. D. Badman,
J. P. Lozano-Kuehne,
X. Liu,
I. R. Macpherson,
I. Zubairi,
R. D. Baird,
N. Rosenfeld,
J. Garcia-Corbacho,
N. Cresti,
R. Plummer,
A. Armstrong,
R. Allerton,
D. Landers,
H. Nicholas,
L. McLellan,
A. Lim,
F. Mouliere,
O. E. Pardo,
M. J. Seckl June 2022
Publication
Nature Communications